MedTrace Logo

Bipolar Radiofrequency Ablation Plus Argon Beam Coagulator Ablation for Atrial Fibrillation

NCT02424110 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-01-27

No results posted yet for this study

Summary

The objective of the study is to make up the technique blind spots of the bipolar radiofrequency ablation in the surgical treatment of atrial fibrillation with rheumatic heart disease by using argon beam coagulator. And to improve the rates of cardioversion of atrial fibrillation after surgery, to decrease the long-term recurrence rate of atrial fibrillation and to compare the early term and long term outcomes of bipolar radiofrequency ablation and bipolar radiofrequency plus argon beam coagulator ablation.

Conditions

Interventions

PROCEDURE

argon beam coagulator ablation

The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.

PROCEDURE

bipolar radiofrequency ablation

The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.

DEVICE

argon beam coagulator （American，Valleylab）

Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group

DEVICE

bipolar radiofrequency (AtricuteTM)

The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group

Sponsors & Collaborators

  • Xinqiao Hospital of Chongqing

    lead OTHER

Principal Investigators

  • Lin Chen · Department of Cardiovascular Surgery, Xinqiao Hospital, Third Military Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02424110 on ClinicalTrials.gov